Drugs in Dev. Pulmonary/Respiratory Diseases
Phase IV
United States 
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theravance Biopharma Announces Results from Phase 4 YUPELRI® PIFR-2 Study in COPD Patients
Details : Yupelri (revefenacin) is a novel small molecule, M3 receptor inhibitor. It is under phase 4 clinical studies in patients with severe to very severe chronic obstructive pulmonary disease (COPD).
Product Name : Yupelri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study
Details : Enrollment of first patient in the Phase 4 PIFR-2 for YUPELRI® (revefenacin) is on the basis of continued investment in controlled clinical studies, that design to personalized treatment plans in order to make better-informed decisions for their COPD pa...
Product Name : Yupelri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2022
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gsk Confirms Therapeutic Efficacy of COPD Triple-Therapy Inhaler
Details : Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is being evaluated in phase 4 clinical trials in combination with umeclidinium & vilanterol for the treatment of chronic obstructive pulmonary disease.
Product Name : Trelegy Ellipta
Product Type : Steroid
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A total of 50 (90.9 percent) PT and 75 (88.2 percent) TNT neonates achieved a ≥25 percent decrease in OI/SOI during treatment with INOmax.
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Submits ANDA For Generic ADVAIR DISKUS®
Details : Respirent Pharmaceuticals has summited an Abbreviated New Drug Application for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. FDA. The product is the generic equivalent of ADVAIR DISKUS of Glax...
Product Name : Flovent Diskus
Product Type : Steroid
Upfront Cash : Inapplicable
January 04, 2021
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
